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Abstract: Secretory carcinoma of the skin is a rare adnexal carcinoma,
which is morphologically and immunohistochemically identical to se-
cretory carcinoma of the breast and is associated with the presence of t
(12;15) translocation, resulting in the ETV6-NTRK3 gene fusion.
Nineteen cases of primary cutaneous secretory carcinoma have been
previously published in the literature. In this study, we describe 6 new
cases of secretory carcinoma of the skin. The study group consisted of
5 female patients and 1 male patient, ranging in age from 57 to
98 years (mean: 74.2, median: 74). Locations included the axilla (2),
neck, eyelid, thigh, and nipple base, each one. Microscopically, all but
1 tumor were well circumscribed and nonencapsulated and exhibited
characteristic abundant secretions within the microcystic and tubular
spaces comprised by bland oval, round to cuboidal neoplastic cells. In
addition, solid areas and focal pseudopapillae were seen, and, in 1
case, a focal mucinous component with small lakes of mucin con-
taining small tumor nests or tubules of the neoplastic cells was present.
The remaining neoplasmwas mostly solid and papillary, with only few
characteristic lumina containing secretions. Immunohistochemically,
all cases expressed S-100 protein, mammaglobin, STAT5, GATA3,
and NTRK. ETV6-NTRK3 gene fusion was detected in 5 cases,
whereas, in the remaining tumor, a novel NFIX-PKN1 gene fusion
was found.
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carcinoma, adnexal neoplasms, ETV6-NTRK3, NFIX-PKN1,
fusion
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Primary cutaneous secretory carcinoma is a rare adnexalcarcinoma that is histopathologically identical to homolo-
gous neoplasms in the salivary gland and breast.1–7 It was
recognized in the skin in 2009.8 Since then, 19 cases have been
reported, mostly as isolated case reports, with only a small
series of 6 cases.2,8–19 In addition to the distinctive histo-
pathologic appearances, cutaneous secretory carcinoma seems
to be associated with the characteristic balanced t(12;15) (p13;
q25) ETV6-NTRK3 translocation, akin to their mammary and
salivary gland counterparts.2 Herein, we report a series of 6
new cases of secretory carcinoma of the skin, including new
microscopic features and a novel NFIX-PKN1 translocation.
MATERIAL AND METHODS
Case Selection
Six cases of secretory carcinoma of the skin were
identified, prospectively or retrospectively, in the consultation
and institutional databases of the authors (2009-2018). None
of the cases was previously published. Follow-up information
was provided by attending physicians.
Immunohistochemical Studies
Immunohistochemical staining was performed on 4-μm-
thick sections, cut from formalin-fixed, paraffin-embedded
tissue, using a Ventana BenchMark XT automated stainer
(Ventana Medical Systems, Tucson, AZ), according to the
manufacturer’s protocol.
The following antibodies were used: S-100 protein
(polyclonal; RTU; Ventana), STAT5 (E289, 1:500, AbCam),
mammaglobin (clone 304-1A5; RTU; DakoCytomation),
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NTRK (A7H6R, 1:25; Cell Signaling), GATA3 (clone L50-
823; 1:200; BioCareMedical), CK7 (clone OV-TL 12/30;
1:200; DakoCytomation), TTF-1 (8G7G3/1, 1:100, Dako),
p63 (clone 4A4; RTU; Ventana), and CD117 (polyclonal,
1:800, Dako). The panel varied between individual cases
depending on the origin.
Molecular Genetic Studies and Fluorescence
In Situ Hybridization
Detection of ETV6-NTRK3 Fusion and NFIX-PKN1
Fusion Transcript by Reverse Transcription
Polymerase Chain Reaction
RNA was extracted using the RecoverAll Total Nucleic
Acid Isolation Kit (Ambion, Austin, TX). cDNA was syn-
thesized using the Transcriptor First Strand cDNA Synthesis
Kit (RNA input 500 ng) (Roche Diagnostics). All procedures
were performed according to the manufacturer’s protocols.
Amplification of a 105 bp product and a 133 bp product of the
β2-microglobulin gene, and a 247 bp product of the PGK gene,
was used to test the quality of the extracted RNA, as previously
described.20–22
For polymerase chain reaction (PCR), 2 μL of cDNA
was added to the reaction, which consisted of 12.5 μL of
HotStar Taq PCR Master Mix (Qiagen, Hilden, Germany),
10 pmol of each primer, and distilled water up to 25μL.23,24
The amplification program comprised denaturation at 95°C for
14 minutes followed by 45 cycles of denaturation at 95°C for
1 minute; annealing at temperatures 60°C was carried out
for 1 minute and extension at 72°C for 1 minute. The proce-
dure was completed by incubation at 72°C for 7 minutes.
Successfully amplified PCR product was purified with
magnetic particles using Agencourt AMPure (Agencourt
Bioscience Corporation, A Beckman Coulter Company,
Beverly, MA). The product was then bidirectionally se-
quenced using Big Dye Terminator Sequencing Kit (PE/
Applied Biosystems, Foster City, CA) and purified with
magnetic particles using Agencourt CleanSEQ (Agencourt
Bioscience Corporation); all this was carried out according
to the manufacturer’s protocols and run on an automated
sequencer ABI Prism 3130×l (Applied Biosystems) at a
constant voltage of 13.2 kV for 11 minutes.
Detection of ETV6 and NTRK3 by Fluorescence
In Situ Hybridization Method
Four-μm-thick FFPE sections were placed onto pos-
itively charged slides. Hematoxylin and eosin–stained slides
were examined for determination of areas for cell counting. The
unstained slides were routinely deparaffinized and incubated in
the 1× Target Retrieval Solution Citrate pH 6 (Dako,
Glostrup, Denmark) at 95°C/40 minutes and subsequently
cooled for 20 minutes at room temperature in the same sol-
ution. The slides were washed in deionized water for 5 minutes,
and they were digested in protease solution with Pepsin (0.5
mg/mL) (Sigma Aldrich, St Louis, MO) in 0.01M HCl at 37°
C/25 to 60 minutes, according to the sample conditions. The
slides were then placed in deionized water for 5 minutes, de-
hydrated in a series of ethanol solution (70%, 85%, and 96% for
2min each), and air-dried.
For the detection of ETV6 rearrangement, a com-
mercial probe, Vysis ETV6 Break Apart FISH Probe Kit
(Vysis/Abbott Molecular, Illinois), was used. The ETV6
probe was mixed with water and LSI/WCP (Locus-Specific
Identifier/Whole Chromosome Painting) hybridization buffer
(Vysis/Abbott Molecular) in a 1:2:7 ratio, respectively. The
probe for the detection of the rearrangement of the NTRK3
gene region was mixed from custom-designed SureFISH
probes (Agilent Technologies Inc., Santa Clara, CA). Chro-
mosomal regions for NTRK3 break-apart probe oligos are
chr15:87501469-88501628 and chr15:88701444-89700343. The
probe mixture was prepared from corresponding probes (each
color was delivered in a separated well), deionized water, and
LSI Buffer (Vysis/Abbott Molecular) in a 1:1:1:7 ratio, re-
spectively. An appropriate amount of mixed probe was ap-
plied on specimens, covered with a glass coverslip, and sealed
with rubber cement. The slides were incubated in the Ther-
moBrite instrument (StatSpin/Iris Sample Processing, West-
wood, MA) with co-denaturation at 85°C/8 minutes and
hybridization at 37°C/16 hours. The rubber-cemented cover-
slip was then removed, and the slide was placed in the post-
hybridization wash solution (2×SSC/0.3% NP-40) at 72°C/
2 minutes. The slide was air-dried in the dark, counterstained
with 4′, 6′-diamidino-2-phenylindole (DAPI; Vysis/Abbott
Molecular), coverslipped, and immediately examined.
The sections were examined with an Olympus BX51
fluorescence microscope (Olympus Corporation, Tokyo,
Japan) using a ×100 objective and the filter sets Triple Band
Pass (DAPI/SpectrumGreen/SpectrumOrange), Dual Band
Pass (SpectrumGreen/SpectrumOrange), and Single Band
Pass (SpectrumGreen or SpectrumOrange).
For each probe, 100 randomly selected nonoverlapping
tumor cell nuclei were examined for the presence of yellow or
green and orange fluorescent signals. Yellow signals were
considered negative, and separate orange and green signals
were considered as positive. Cutoff values were set to >10%
of nuclei with chromosomal breakpoint signals (mean, +3 SD
in normal non-neoplastic control tissues).
Detection of ETV6-NTRK3 and NFIX-PKN1 Fusion
Transcripts by Next-generation Sequencing
For next-generation sequencing (NGS) studies, 2 to 3
FFPE sections (10 μm thick) were macrodissected to isolate
tumor-rich regions. The samples were extracted for total
nucleic acid using Agencourt FormaPure Kit (Beckman
Coulter, Brea, CA), following the corresponding protocol
with overnight digestion and an additional 80°C in-
cubation, as described in the modification of the protocol
by ArcherDX (ArcherDX Inc., Boulder, CO).
Total nucleic acid was quantified using the Qubit
Broad Range RNA Assay Kit (Thermo Fisher Scientific)
and 2 μL of sample.
RNA Integrity Assessment and Library
Preparation for NGS
Unless otherwise indicated, 250 ng of FFPE RNA
was used as input for NGS library construction. To assess
RNA quality, the PreSeq RNA QC Assay using iTaq
Universal SYBR Green Supermix (Biorad, Hercules, CA)
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was performed on all samples during library preparation
to generate a measure of the integrity of RNA (in the form
of a cycle threshold [Ct] value). Library preparation and
RNA QC were performed following the Archer Fusion
Plex Protocol for Illumina (ArcherDX Inc.). The Archer
FusionPlex Solid Tumor Kit (covering 53 genes) was used.
Final libraries were diluted 1:100,000 and quantified in a
10 µL reaction following the Library Quantification for
Illumina Libraries protocol and assuming a 200 bp frag-
ment length (KAPA, Wilmington, MA). The concen-
tration of final libraries was around 200 nM. Threshold
representing the minimum molar concentration for which
sequencing can be robustly performed was set at 50 nM.
NGS Sequencing and Analysis
Libraries were sequenced on a NextSeq. 500 se-
quencer (Illumina, San Diego, CA). They were diluted to
4 nM, and equal amounts of up to 30 libraries were pooled
per run. The optimal number of raw reads per sample was
set to 3,000,000. Library pools were diluted to 1.8 pM
library stock spiked with 20% PhiX and loaded in the
NextSeq MID cartridge. Analysis of sequencing results
was performed using the Archer Analysis software (v5.1.7;
ArcherDX Inc.). Fusion parameters were set to a mini-
mum of 5 valid fusion reads with a minimum of 3 unique
start sites within the valid fusion reads.
RESULTS
Clinical Features
There were 5 female patients and 1 male patient, with
ages ranging at diagnosis from 57 to 98 (mean: 74.2, median:
74). Location included axilla (n=2), neck (n=1), eyelid (n=1),
thigh (n=1), and nipple base (n=1). All skin tumors occurred
as solitary nodules (Fig. 1). The patient with the lesion
involving the nipple was a 75-year-old woman, who noticed
uncomfortable rash to her right breast, above the nipple, for
2 months, with nipple protrusion. Her mammograms and
breast ultrasound were negative at that time but magnetic
FIGURE 1. Case 4. A 15×10mm slowly growing (8mo) pain-
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resonance imaging was suspicious for malignancy in a right
axillary lymph node, which was biopsied and turned positive
for metastatic adenocarcinoma of a probable breast origin,
with the following phenotype ER−, PR−, HER2-neu−, Ki-67
− 5%. A punch biopsy of the right nipple lesion was performed,
and the diagnosis of secretory carcinoma was established on the
basis of detection of ETV6-NTRK3 fusion. Subsequent PET/
CT revealed a hypermetabolic spot in the area of the seventh
left rib. The patient had a history of a sixth left rib fracture
about a year ago that was said to be due to a fall. There was a
question whether the PET activity was due to the previous
trauma or represented a metastatic disease. Finally, right
central partial mastectomy was performed. No tumor in the
breast parenchyma was found. In the other 5 cases, all
neoplasms were surgically excised, with a conventional elliptical
excision. In one case, reexcision was performed. None of these
patients had evidence of disease (follow-up ranged from 2 to 32
mo) (Table 1).
Histopathologic Features
Of the 6 lesions, 5 manifested typical features with
characteristic abundant intraluminal secretions within
closely packed microcystic and tubular spaces comprised
of bland oval, round to cuboidal neoplastic cells. In ad-
dition, solid areas and focal pseudopapillae were seen.
When assessable, most tumors were relatively well cir-
cumscribed, nonencapsulated, and confined to the dermis
(Fig. 2).
In one case (case 5), there was a focal mucinous
component which was less regular and extended focally
into the subcutis. It was composed of small lakes of
mucin-containing tubules of the neoplastic cells or small
tumor nests. Mucinous lacunae were often seen at the
periphery of the intact tubules that gradually disappeared.
Rare tubules contained a preserved peripheral basal/my-
oepithelial cell layer, likely representing an in situ lesion or
preexisting eccrine/apocrine duct (Fig. 3). Another lesion
containing an in situ component was the tumor from the
nipple.
The lesion from the eyelid (case 4) was mostly solid
and papillary, showing both micropapillae and true papillae
with a fibrous core; characteristic lumina containing secre-
tions were less conspicuous in comparison with the other 5
neoplasms. There also were variably sized lumina (some
markedly distended) with apocrine or colloid-like secretion.
Focally, the cells in this neoplasm assumed hobnail ap-
pearances, and there were areas with larger “blastoid” cells,
but no high-grade atypia was evident (Fig. 4).
In no case was ulceration of the epidermis, peri-
neural invasion, and lymphovascular involvement found.
In neither axillary cases was there any evidence of residua
of mammary tissue. The mitotic rate ranged from 0 to 4
mm2. The lymph node metastasis from the nipple lesion
(case 6) was not available for histopathologic review.
Immunohistochemical Findings
Neoplastic cells were positive for S-100 protein,
mammaglobin, STAT5, GATA3, and NTRK. The neo-
plasm with a mucinous component (case5) manifested
some differences between the mucinous and conventional
parts, namely S-100 protein was weak and focal in the
main bulk of the tumor with the conventional appearance,
FIGURE 2. Whole-mount sections of 6 cases, 4 of which are well circumscribed. Case 4 shows a focal invasion into the subcutis,
and the tumor on the nipple (case 6) has irregular outlines.
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whereas diffuse positivity was seen in the mucinous moi-
ety. There was also the loss of p63 in the mucinous areas
compared with the conventional parts. The panel for each
individual case is listed in Table 1.
Gene Fusions
In 5 cases, ETV6-NTRK3 translocation was detected,
whereas, in the remaining case, a novel in-frame NFIX-
PKN1, with breakpoints located in exon 8 of the NFIX gene
and exon 13 of the PKN1 gene, was found. The fusions were
detected in 5 cases by NGS and confirmed by either
break-apart fluorescence in situ hybridization (FISH) or re-
verse transcription polymerase chain reaction (RT-PCR) in 4
and 3 cases, respectively. In one case, only RT-PCR was
used to detect the translocation (Table 1). In case of the
NFIX-PKN1 fusion, it was impossible to use FISH break-
apart probes for validation, inasmuch as the genes are
located too close to one another.
DISCUSSION
Our series extends the histopathologic spectrum of
secretory carcinoma of the skin and the spectrum of its
FIGURE 3. Secretory carcinoma with a novel NFIX-PKN1 fusion (case 5). The typical appearance of closely packed microcysts and
tubules lined by bland cells with characteristic abundant bubbly secretion (A). The mucinous component with small lakes of mucin,
spilling into the surrounding dermis containing partly preserved or destroyed tubules. Note lacunae of the mucus located at the
periphery of relatively intact tubules (B). The duct containing incipient secretions and intact peripheral basal/myoepithelial cell
layer, likely representing preexisting apocrine/eccrine duct (an in situ lesion) (C, arrow). Positivity of p63 for the abluminal cells in
the upper part of the tumor and loss of p63 expression in the mucinous areas (D). Screenshot from the Archer Analysis software,
depicting the details of the detected NFIX-PKN1 fusion: SS—the number of unique start sites supporting the event. Reads—the
number of unique reads supporting the event. %Reads—the percent of reads supporting the event. Strong—True/False value
indicating whether the Fusion has passed all Strong Evidence filters. Brkpt—True/False value indicating whether the Fusion has
passed all Strong Evidence filters. InFrame—True/False/Unknown value indicating whether the event is predicted to be in-frame,
and thus a functional transcript (E).
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genetic alterations. Although most cases had typical his-
topathologic appearances, 2 cases are worthy of a short
comment. In one case (case 5), in addition to conventional
areas, there was a minor mucinous component, which has
not been reported in skin lesions, to the best of our
knowledge. However, a similar salivary gland tumor was
included in the series of Skalova et al25 (Fig. 2A). Notably,
this mucinous component had slightly different
immunophenotype from that in the main bulk of the
lesion with respect to S-100 protein and p63 expression.
Moreover, there were structures with an intact basal/
myoepithelial cell layer but typical secretions, likely
representing an in situ lesion in a preexisting duct. A
similar feature has been documented in the paper by
Huang et al.15
The tumor on the eyelid was unusual in that it had rel-
atively few areas with typical closely packed lumina filled with
secretions. The tumor instead was mainly composed of solid,
papillary, and pseudopapillary areas with focal apocrine
or colloid-like secretion. Similar lesions have been, however,
reported both in the skin and salivary glands.7,13 It is known
that in some organs, for example, the thyroid glands,
ETV6-NTRK3 translocation was found in lesions that have
different morphology from secretory carcinoma.26,27 Because
of colloid-like secretion, this case was stained for TTF1 but
proved negative. The patient did not have any evidence of a
primary of the thyroid gland on a clinical work-up. Fur-
thermore, the cells in this case in some areas were larger and
had a blastoid appearance; however, we think this feature does
not qualify for high-grade transformation, an event that has
also been reported in extracutaneous secretory carcinomas.23,24
A purist can argue against considering the case with the
nipple tumor as primary cutaneous. We, however, included this
case on the basis of the fact that the lesion was superficial,
confined to the nipple, and no breast parenchymal involvement
was identified on a thorough work-up and, later, microscopi-
cally, following the mastectomy. It is known that some tumors
typically occurring on the nipple, such as nipple adenoma,
syringomatous adenoma, nodular mucinosis, and nipple pseu-
dolymphoma, are covered by both dermatopathology and
mammary pathology. Moreover, of interest is that this patient
and another patient with a tumor in the axilla are the oldest
individuals with secretory carcinoma ever reported (75 and
98 y, respectively).
In all but 1 case,ETV6-NTRK3 translocation was found.
In the remaining case, an NFIX-PKN1 fusion was detected.
The latter has been previously described in neither cutaneous
secretory carcinoma nor in extracutaneous homonymous tu-
mors. In fact, this fusion has not been reported at all, to the best
of our knowledge. Nuclear factor I, X-type (NFIX) gene is
FIGURE 4. Secretory carcinoma of the eyelid (case 4). Numerous micropapillary structures and true papillae with a fibrous core
within cystic spaces (A). The colloid-like (moth eaten) spaces with abundant secretion (B) and microcystic area containing
abundant eosinophilic secretion (C). Atypical neoplastic cells with large nuclei (2 to 3 times larger than a majority of tumor cells)
and pronounced nucleoli (D, arrows).
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located on 19p13 and codes for a ubiquitous 47-kD dimeric
DNA-binding protein, belonging to a family of transcription
factors. Pathogenic variants of NFIX have also been reported
as causative of Marshall-Smith Syndrome and Malan syn-
drome (Sotos syndrome 2).28,29 The Protein kinase-1 (PKN1)
gene is also located on 19p13 and codes for protein belonging
to the protein kinase C superfamily that is activated by the
Rho family of small G proteins and may mediate the Rho-
dependent signaling pathway. Mutations in PKN1 gene were
described in rhabdomyosarcoma.30
Apart from the ETV6-NTRK3 translocation, other
gene fusions reported in secretory carcinoma in different
organs include ETV6-RET, ETV6-MET, and dual fusion
ETV6-NTRK3 and ETV6-MAML3.7,31,32 Cases of secre-
tory carcinoma of the salivary gland with NCOA4-RET
and TRIM27-RET gene fusions have subsequently been
reclassified as intraductal carcinomas.31,33
In conclusion, we have described 6 new cases of secretory
carcinoma involving the skin. Adding this series to the pre-
viously published 19 cases, it can be summarized that cuta-
neous secretory carcinoma mainly occurs in female individuals
(female 16, male 9). The ages of the patients ranged from 13 to
98 years (mean: 51.8, median: 51.5). The most common loca-
tion is the axilla (n=10) followed by the neck (n=3), and lip
(n=3). The tumors seem to follow an indolent course, without
recurrence and metastasis. ETV6-NTRK3 translocation has
been identified in 22 of the 25 studied cases, and 1 case had a
heterozygous deletion ofETV6 in 25% of cells.11We extend the
spectrum of translocations by reporting a novel NFIX-PKN1
translocation and broaden the histopathologic spectrum by
adding a case with a mucinous component.
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